<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170507</url>
  </required_header>
  <id_info>
    <org_study_id>RAC 2101042</org_study_id>
    <nct_id>NCT01170507</nct_id>
  </id_info>
  <brief_title>Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation</brief_title>
  <official_title>Magnitude of Changes in 25 OH Vitamin D3 Levels After Vitamin D3 Supplementation: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King Faisal Specialist Hospital &amp; Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>King Faisal Specialist Hospital &amp; Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D deficiency is common world wide. 25 OH vitamin D level is the best indicator of
      vitamin D status. The determination of the appropriate dose of vitamin D supplement is
      essential for management of vitamin D deficiency as well as for designing vitamin D
      fortification programs. The increments in 25 OH vitamin D levels following various doses of
      vitamin D supplement for different genders, body weights, and starting 25 OH vitamin D level
      have not been well defined. The time course of depletion of repleted vitamin D stores is also
      not known.

      The investigators plan to conduct a double blind randomized study on 9 cohorts to determine
      levels of 25 OH vitamin D following supplementation with different doses of vitamin D3 for 5
      months and their withdrawal for 3 months.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Slope of 25 OH vitamin D3 level vs vitamin D3 dose</measure>
    <time_frame>5 months</time_frame>
    <description>The primary endpoint is the slope of the dose (vitamin D3)- response (25 OH vitamin D3 level) curve for each cohort. The slope of the placebo group will be used to determine changes in 25 OH vitamin D3 levels that are not related to study intervention. The slope will be determined over 5 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>slope of vitamin D3 level vs vitamin D3 dose</measure>
    <time_frame>5 months</time_frame>
    <description>slope of vitamin D3 level vs vitamin D3 dose over 5 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hypercalcemia</measure>
    <time_frame>8 months</time_frame>
    <description>incidence of hypercalcemia over 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of hypercalciuria</measure>
    <time_frame>8 months</time_frame>
    <description>incidence of hypercalciuria over 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>slope of decline of 25 OH vitamin D3 level vs time</measure>
    <time_frame>3 months</time_frame>
    <description>slope of decline of 25 OH vitamin D3 level vs time over 3 months</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>vitamin D3 1000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 3000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 5000 IU</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3 1000 IU orally daily for 5 months</intervention_name>
    <arm_group_label>vitamin D3 1000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3 3000 IU orally daily for 5 months</intervention_name>
    <arm_group_label>Vitamin D3 3000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D3 5000 IU orally daily for 5 months</intervention_name>
    <arm_group_label>Vitamin D3 5000 IU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo orally daily for 5 months</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults living in Riyadh area who consume no more than one serving of milk/day, do not
             take vitamin supplement, habitually have less than 10 hr of sun exposure per week,
             don't suffer from granulomatous conditions, liver disease, or kidney disease, and
             don't take anticonvulsants, barbiturates, or steroids.

          -  Individuals with with total 25 OH vitamin D level exceeding 100 nmol/l will be
             excluded from the study. Individuals with 25 OH vitamin D levels less than 20 nmol/L
             will be excluded from the placebo arm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muhammad M Hammami, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>King Faisal Specialist Hospital &amp; Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>King Faisal Specialist Hospital &amp; Research Center</name>
      <address>
        <city>Riyadh</city>
        <zip>11211</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Saudi Arabia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>King Faisal Specialist Hospital &amp; Research Center</investigator_affiliation>
    <investigator_full_name>Muhammad Maher Hammami</investigator_full_name>
    <investigator_title>Chairman, Department of Clinical Studies &amp; Empirical Ethics</investigator_title>
  </responsible_party>
  <keyword>vitamin D3, 25 OH vitamin D3 level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

